|
|
Vaccine Detail
|
MAGE-A1, Her-2/neu, FBP peptides ovarian cancer vaccine |
| Vaccine Information |
- Vaccine Name: MAGE-A1, Her-2/neu, FBP peptides ovarian cancer vaccine
- Target Pathogen: Cancer
- Target Disease: Cancer
- Type: Subunit vaccine
- Status: Clinical trial
- Host Species for Licensed Use: None
- Antigen: MAGE-A1:161-169, FBP:1901-199, Her-2/neu:369-377, MAGE-A1:96-104, and Her-2/neu:754-762 (NCT00373217; NCIT_C62775)
- Immunization Route: subcutaneous injection
- Description: This is a synthetic cancer vaccine comprised of multiple peptides derived from MAGE-1A, Her-2/neu, and folate binding protein (FBP), with potential immunostimulating and antineoplastic properties. The MAGE-A1, Her-2/neu, FBP peptides cancer vaccine includes the peptides MAGE-A1:161-169, FBP:191-199, Her-2/neu:369-377, MAGE-A1:96-104, and Her-2/neu:754-762. Vaccination with this cancer vaccine may activate the immune system to mount a cytotoxic T-cell (CTL) response against tumor cells expressing the corresponding antigens, resulting in tumor cell lysis. (NCIT_C62775) The vaccine compromises synthetic ovarian cancer-associated peptides administered with a synthetic tetanus toxoid helper peptide emulsified in Montanide ISA-51 before or after paclitaxel and carboplatin in patients with stage III-IV ovarian epithelial, primary peritoneal cavity, or fallopian tube cancer undergoing optimal cytoreductive surgery. Vaccines made from peptides may help the body build an effective immune response to kill tumor cells. Drugs used in chemotherapy, such as paclitaxel and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving chemotherapy before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed. Giving vaccine therapy and chemotherapy after surgery may kill any tumor cells that remain after surgery. (NCT00373217)
|
| Host Response |
|
|
| References |
NCIT_C62775: MAGE-A1, Her-2/neu, FBP Peptides Cancer Vaccine [https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C62775]
NCT00373217: Vaccine Therapy, Paclitaxel, and Carboplatin in Treating Patients Who Are Undergoing Surgery for Stage III or Stage IV Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer [https://clinicaltrials.gov/study/NCT00373217]
|
|
